OBJECTIVE: To estimate whether mammography can be an early, valid tool for predicting the development of coronary heart disease (CHD) in women.
METHODS: Women presenting for routine mammograms between June and August 2004 were recruited for the study. Baseline data collected included risk factors and family history of heart disease, as well as any cardiac events experienced by the patient. Similar follow-up data were collected during subsequent years, and these patient-completed surveys were correlated with the baseline mammograms screened for breast arterial calcifications.
RESULTS: Throughout the 5-year follow-up, CHD was present in 20.8% of women who screened positive for breast arterial calcification and in 5.4% of who screened negative for breast arterial calcification (P<.001). Among women who did not have CHD at baseline, breast arterial calcification-positive women were more likely to develop CHD or a stroke than those who were breast arterial calcification-negative (6.3% compared with 2.3%, P=.003; and 58.3% compared with 13.3%, P<.001), respectively. These results remained significant even when controlling for age.
CONCLUSION: The presence of breast arterial calcifications on mammograms indicates a significantly increased risk of developing CHD or a stroke. These results suggest that breast arterial calcifications should be routinely reported on mammograms and viewed as a marker for the development of CHD.
LEVEL OF EVIDENCE: II
The presence of breast arterial calcifications on screening mammography is a risk factor for the future development of coronary heart disease.
From the Departments of Obstetrics and Gynecology and Internal Medicine, The Reading Hospital and Medical Center, Reading, Pennsylvania; the Departments of Obstetrics and Gynecology and Internal Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania; and the School of Osteopathic Medicine, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania.
Funded by the research budgets of the Reading Hospital and Medical Center and Hartford Hospital.
Presented in abstract form at the 2009 Annual Meeting of the North American Menopause Society, October 1, 2009, San Diego, California.
Corresponding author: Peter F. Schnatz, DO, FACOG, FACP, NCMP, Associate Chairman and Residency Program Director, The Reading Hospital and Medical Center, Department of ObGyn-R1; PO Box 16052, Reading, PA 19612-6052; e-mail: firstname.lastname@example.org.
Financial Disclosure The authors did not report any potential conflicts of interest.